INTRODUCTION
The three endogenous isoforms of endothelin (ET) [1] in humans, ET-1, ET-2 and ET-3, mediate their actions via two receptor subtypes, ET A and ET B , that have been isolated and cloned from mammalian tissues [2, 3] . Both subtypes belong to the seven-transmembrane-domainspanning, G-protein-coupled receptor superfamily [4, 5] . The only other endogenous peptides displaying a high degree of sequence similarity to the ETs are the sarafotoxins (S6a, S6b, S6c and S6d), a family of 21-amino-acid peptides isolated from the venom of the snake Atractaspis engadensis. ET receptors are widely expressed in all tissues, consistent with the physiological role of ET-1, the most abundant isoform, as a ubiquitous endotheliumderived vasoactive peptide contributing to the maintenance of normal vascular tone. Receptors are also localized to non-vascular structures (such as epithelial cells) and expressed in the central nervous system (glia and neurons).
In human blood vessels, ET A receptors are present mainly on vascular smooth muscle cells, and are chiefy responsible for contraction, but in animals this can vary depending on the species and vascular bed. In some blood vessels, particularly from the rabbit, ET B receptors mediate vasoconstriction. In blood vessels from other species, ET-1 is thought to mediate vasoconstriction by activating both receptor subtypes. ET B receptors are also thought to be localized to the single layer of endothelial cells lining the vessel wall. Activation of endothelial ET B receptors may lead to the release of endothelium-derived relaxing factors (nitric oxide and prostanoids). Nonvascular ET B receptors in organs including the kidney may beneficially clear ET-1 from the circulation [5] .
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ET stimulates proliferation in a number of different cell types, including smooth muscle cells (mainly via the ET A subtype) and astrocytes (via ET B ). In most of these cells, ET is thought to be co-mitogenic, potentiating the actions of other growth factors, such as platelet-derived growth factor.
AGONISTS
ET receptors continue to be classified (Table 1) 
ANTAGONISTS
Antagonists are currently classified as ET A -selective, ET B -selective, or mixed antagonists that display similar affinities for both receptor subtypes [5, 6] . However, only ET A -selective or ET A \ET B antagonists are currently being evaluated in clinical trials, although the precise pharmacological profile of antagonists required for a particular disease indication is still debated ( Table 2 ). The most highly selective peptide antagonists (4-5 orders of selectivity) for the ET A receptors are the cyclic of the molar concentration of an antagonist that makes it necessary to double the concentration of agonist required to elicit the original submaximal response). However, they are less selective, and plasma binding may also be significant in vivo.
A limited number of peptide and non-peptide ET B receptor antagonists have been developed, reflecting the lack of clinical need for this type of compound. They are less potent than ET A antagonists and display lower selectivity (usually only 1-2 orders of magnitude) for the ET B subtype.
The distinction between antagonists that are ET Aselective and those that block both ET A and ET B receptors is not precise, but generally the former display greater than 100-fold selectivity for the ET A subtype and the latter less than 100-fold. These compounds are seldom reported as having equal affinity for both subtypes, and this should be taken into consideration in experimental designs.
Table 2 Classification of ET receptor antagonists in clinical development
Tracleer is the first ET antagonist to receive approval from the Food and Drug Administration for the treatment of pulmonary arterial hypertension [7] . CHF, congestive heart failure; PC, prostate cancer; PH, primary pulmonary hypertension. 
